These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

661 related items for PubMed ID: 18823687

  • 1. Effect of renin-angiotensin-aldosterone system inhibition, dietary sodium restriction, and/or diuretics on urinary kidney injury molecule 1 excretion in nondiabetic proteinuric kidney disease: a post hoc analysis of a randomized controlled trial.
    Waanders F, Vaidya VS, van Goor H, Leuvenink H, Damman K, Hamming I, Bonventre JV, Vogt L, Navis G.
    Am J Kidney Dis; 2009 Jan; 53(1):16-25. PubMed ID: 18823687
    [Abstract] [Full Text] [Related]

  • 2. Elevated N-terminal pro-brain natriuretic peptide levels predict an enhanced anti-hypertensive and anti-proteinuric benefit of dietary sodium restriction and diuretics, but not angiotensin receptor blockade, in proteinuric renal patients.
    Slagman MC, Waanders F, Vogt L, Damman K, Hemmelder M, Navis G, Laverman GD.
    Nephrol Dial Transplant; 2012 Mar; 27(3):983-90. PubMed ID: 21862455
    [Abstract] [Full Text] [Related]

  • 3. Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial.
    Tylicki L, Rutkowski P, Renke M, Larczyński W, Aleksandrowicz E, Lysiak-Szydlowska W, Rutkowski B.
    Am J Kidney Dis; 2008 Sep; 52(3):486-93. PubMed ID: 18423812
    [Abstract] [Full Text] [Related]

  • 4. Effects of antiproteinuric intervention on elevated connective tissue growth factor (CTGF/CCN-2) plasma and urine levels in nondiabetic nephropathy.
    Slagman MC, Nguyen TQ, Waanders F, Vogt L, Hemmelder MH, Laverman GD, Goldschmeding R, Navis G.
    Clin J Am Soc Nephrol; 2011 Aug; 6(8):1845-50. PubMed ID: 21784839
    [Abstract] [Full Text] [Related]

  • 5. Fibroblast growth factor 23 and the antiproteinuric response to dietary sodium restriction during renin-angiotensin-aldosterone system blockade.
    Humalda JK, Lambers Heerspink HJ, Kwakernaak AJ, Slagman MC, Waanders F, Vervloet MG, Ter Wee PM, Navis G, de Borst MH, NIGRAM Consortium.
    Am J Kidney Dis; 2015 Feb; 65(2):259-66. PubMed ID: 25278093
    [Abstract] [Full Text] [Related]

  • 6. Impact of combined losartan/hydrochlorothiazide on proteinuria in patients with chronic kidney disease and hypertension.
    Fujisaki K, Tsuruya K, Nakano T, Taniguchi M, Higashi H, Katafuchi R, Kanai H, Nakayama M, Hirakata H, Kitazono T, Impact of Combined Losartan/Hydrochlorothiazide on Proteinuria in Patients with Chronic Kidney Disease and Hypertension (ILOHA) Study Investigators.
    Hypertens Res; 2014 Nov; 37(11):993-8. PubMed ID: 24965167
    [Abstract] [Full Text] [Related]

  • 7. Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan.
    Vogt L, Waanders F, Boomsma F, de Zeeuw D, Navis G.
    J Am Soc Nephrol; 2008 May; 19(5):999-1007. PubMed ID: 18272844
    [Abstract] [Full Text] [Related]

  • 8. Renal tubular function and urinary N-acetyl-β-d-glucosaminidase and kidney injury molecule-1 levels in asthmatic children.
    Demir AD, Goknar N, Oktem F, Özkaya E, Yazıcı M, Torun E, Vehapoğlu A, Kucukkoc M.
    Int J Immunopathol Pharmacol; 2016 Dec; 29(4):626-631. PubMed ID: 27272162
    [Abstract] [Full Text] [Related]

  • 9. High urinary excretion of kidney injury molecule-1 is an independent predictor of graft loss in renal transplant recipients.
    van Timmeren MM, Vaidya VS, van Ree RM, Oterdoom LH, de Vries AP, Gans RO, van Goor H, Stegeman CA, Bonventre JV, Bakker SJ.
    Transplantation; 2007 Dec 27; 84(12):1625-30. PubMed ID: 18165774
    [Abstract] [Full Text] [Related]

  • 10. Renoprotective RAAS inhibition does not affect the association between worse renal function and higher plasma aldosterone levels.
    Gant CM, Laverman GD, Vogt L, Slagman MCJ, Heerspink HJL, Waanders F, Hemmelder MH, Navis G, Holland Nephrology Study (HONEST) Network.
    BMC Nephrol; 2017 Dec 20; 18(1):370. PubMed ID: 29262813
    [Abstract] [Full Text] [Related]

  • 11. Low-dose dual blockade of the renin-angiotensin system improves tubular status in non-diabetic proteinuric patients.
    Renke M, Tylicki L, Rutkowski P, Wojnarowski K, Lysiak-Szydlowska W, Rutkowski B.
    Scand J Urol Nephrol; 2005 Dec 20; 39(6):511-7. PubMed ID: 16303729
    [Abstract] [Full Text] [Related]

  • 12. Kidney injury molecule 1: in search of biomarkers of chronic tubulointerstitial damage and disease progression.
    Perico N, Cattaneo D, Remuzzi G.
    Am J Kidney Dis; 2009 Jan 20; 53(1):1-4. PubMed ID: 19101395
    [No Abstract] [Full Text] [Related]

  • 13. Antiproteinuric efficacy of losartan in comparison with amlodipine in non-diabetic proteinuric renal diseases: a double-blind, randomized clinical trial.
    Praga M, Andrade CF, Luño J, Arias M, Poveda R, Mora J, Prat MV, Rivera F, Galceran JM, Ara JM, Aguirre R, Bernis C, Marín R, Campistol JM.
    Nephrol Dial Transplant; 2003 Sep 20; 18(9):1806-13. PubMed ID: 12937228
    [Abstract] [Full Text] [Related]

  • 14. Kidney injury molecule-1 and N-acetyl-β-D-glucosaminidase in chronic heart failure: possible biomarkers of cardiorenal syndrome.
    Jungbauer CG, Birner C, Jung B, Buchner S, Lubnow M, von Bary C, Endemann D, Banas B, Mack M, Böger CA, Riegger G, Luchner A.
    Eur J Heart Fail; 2011 Oct 20; 13(10):1104-10. PubMed ID: 21846754
    [Abstract] [Full Text] [Related]

  • 15. High urinary excretion of kidney injury molecule-1 is an independent predictor of end-stage renal disease in patients with IgA nephropathy.
    Peters HP, Waanders F, Meijer E, van den Brand J, Steenbergen EJ, van Goor H, Wetzels JF.
    Nephrol Dial Transplant; 2011 Nov 20; 26(11):3581-8. PubMed ID: 21467131
    [Abstract] [Full Text] [Related]

  • 16. Dual blockade of the renin-angiotensin-aldosterone system with high-dose angiotensin-converting enzyme inhibitor for nephroprotection: an open, controlled, randomized study.
    Tylicki L, Renke M, Rutkowski P, Larczyński W, Aleksandrowicz E, Lysiak-Szydlowska W, Rutkowski B.
    Scand J Urol Nephrol; 2008 Nov 20; 42(4):381-8. PubMed ID: 19230172
    [Abstract] [Full Text] [Related]

  • 17. Antiproteinuric and blood pressure-lowering effects of a fixed-dose combination of losartan and hydrochlorothiazide in hypertensive patients with stage 3 chronic kidney disease.
    Abe M, Okada K, Maruyama T, Matsumoto K.
    Pharmacotherapy; 2009 Sep 20; 29(9):1061-72. PubMed ID: 19698011
    [Abstract] [Full Text] [Related]

  • 18. Add-on angiotensin receptor blockade with maximized ACE inhibition.
    Agarwal R.
    Kidney Int; 2001 Jun 20; 59(6):2282-9. PubMed ID: 11380832
    [Abstract] [Full Text] [Related]

  • 19. Add-on angiotensin II receptor blockade lowers urinary transforming growth factor-beta levels.
    Agarwal R, Siva S, Dunn SR, Sharma K.
    Am J Kidney Dis; 2002 Mar 20; 39(3):486-92. PubMed ID: 11877567
    [Abstract] [Full Text] [Related]

  • 20. Proinflammatory effects of oxidative stress in chronic kidney disease: role of additional angiotensin II blockade.
    Agarwal R.
    Am J Physiol Renal Physiol; 2003 Apr 20; 284(4):F863-9. PubMed ID: 12505865
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.